You are about to access information on our medicines and medical devices aimed exclusively at healthcare professionals.

By virtue of Spanish Royal Decree 1416/1994 of 25 June regulating the advertising of medicinal products for human use, Spanish Royal Decree 1591/2009 of 16 October regulating medical devices and Law 29/2006 of 26 July on the guarantees and rational use of medicines and health products, in this section Bioibérica can only offer advertising content of prescription medicines to health personnel authorised to prescribe or dispense them.

I am a health professional authorised to prescribe or dispense, or a pharma company professional.


Droglican® is indicated for the symptomatic treatment of osteoarthritis of the knee in patients with moderate to severe pain for whom the combined treatment with chondroitin sulfate and glucosamine is indicated.

Information updated January 2019.

Composition and dose

Droglican® contains chondroitin sulfate and glucosamine hydrochloride as active substances, and comes in boxes with 90 hard gelatin capsules which contain 200 mg of chondroitin sulfate and 250 mg of glucosamine hydrochloride each.

The therapeutic dose is 6 capsules per day and it is recommended to take 2 capsules, 3 times per day, to complete this dose, for at least 6 months.

Droglican® is a prescription drug, financed by Social Security, registered in Spain by the Spanish Agency of Medicines and Medical Devices (AEMPS).

It is also approved in other countries. Please contact us for more information.  

Efficacy and safety

Recent clinical studies on patients with osteoarthritis have shown that treatment with Droglican® improves pain, inflammation and joint effusion, and functional deficits, in a clinically relevant manner, and that it has the same level of symptomatic efficacy as celecoxib after 6 months of treatment1,2. Consequently, studies have also shown an improved quality of life for patients.

Additionally, the safety of the active substances contained in Droglican® have been proven in various clinical trials1,2.


1. Hochberg MC, et al. Ann Rheum Dis. 2016 Jan;75(1):37-44.

2. Clegg DO, et al. N Engl J Med. 2006 Feb 23;354(8):795-808.

To consult these studies on Droglican®, apart from the additional bibliography and other relevant contents on osteoarthritis, you can visit


RRP Spain €17.11

Droglican® is financed by Social Security.